<DOC>
	<DOCNO>NCT00115999</DOCNO>
	<brief_summary>The purpose study directly compare safety efficacy intra-thrombus alfimeprase 0.3 mg/kg placebo acute peripheral arterial occlusion ( PAO ) measure 30 day open vascular free surgery rate .</brief_summary>
	<brief_title>Study Alfimeprase Rapidly Dissolve Blood Clots Leg Help Prevent Need Surgery Leg Arteries</brief_title>
	<detailed_description>There unmet medical need improve thrombolytic therapy acute peripheral arterial occlusion ( PAO ) . Currently use plasminogen activator result increase circulating level plasmin result systemic `` lytic state '' distinguish physiologic pathologic thrombosis . In general , mean plasminogen activator infusion duration great 24 hour order achieve successful thrombolysis problematic disease delay restoration arterial flow lead irreversible ischemic damage . A direct thrombolytic agent like alfimeprase , rapid mechanism action potentially safer bleed risk profile , could facilitate rapid restoration arterial flow avoidance open vascular surgery .</detailed_description>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>Must give write informed consent Ages 18 old Acute PAO low extremity onset symptom within 14 day prior randomization Acute index limb ischemia classify SVS/ISCVS Class I IIA cause occlusion native artery and/or bypass graft ( vein prosthetic ) Need open vascular surgical intervention event unsuccessful thrombolysis Available followup assessment Contraindication systemic anticoagulation History endovascular procedure open vascular surgery index limb within last 30 day History significant acute chronic kidney disease would preclude contrast angiography Known allergy contrast agent History heparininduced thrombocytopenia ( HIT ) Participation study investigational device , medication , biologic , agent within 30 day prior randomization Any thrombolytic therapy within 30 day prior randomization Past participation alfimeprase clinical trial History hypersensitivity aspirin Pregnant , lactating , actively menstruate woman woman childbearing potential use adequate contraceptive precaution ( e.g . intrauterine device , oral contraceptive , barrier method , contraception deem adequate investigator ) Uncontrolled hypertension : systolic blood pressure ( BP ) &gt; 180 mmHg , diastolic BP &gt; 110 mmHg time baseline assessment Hematocrit &lt; 30 % ; subject low hematocrit actively bleed enter study transfusion hematocrit &gt; = 30 % Platelet count &lt; 100 X 10 ( 9 ) /L baseline lab Investigator inability advance guidewire index occlusion Medically unable withstand open vascular surgical procedure Any feature , opinion investigator , preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>PAO</keyword>
	<keyword>acute peripheral arterial occlusion</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>blood clot</keyword>
	<keyword>leg attack</keyword>
	<keyword>alfimeprase</keyword>
	<keyword>thrombus</keyword>
	<keyword>embolism</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>claudication</keyword>
	<keyword>thrombolytic</keyword>
	<keyword>thrombosis</keyword>
	<keyword>plasminogen activator</keyword>
	<keyword>arterial flow</keyword>
</DOC>